Industry

FREMONT, Calif.–(BUSINESS WIRE)–Cyber-physical identity access management and security leader AlertEnterprise revealed the addition of its new Asset Governance module to their Guardian security convergence platform. AlertEnterprise Asset Governance connects individual digital identities to physical assets such as keys, computers and company vehicles helping organizations keep tabs on and protect physical assets from the moment they’re … [Read more…]

2022 User Satisfaction Survey names Veradigm Payerpath the top solution for End-To-End RCM Software Technology, supporting Physicians Practices & Ambulatory Facilities/Groups CHICAGO–(BUSINESS WIRE)–$MDRX #healthIT—Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), today announced that Black Book, a healthcare-centric market research and public opinion … [Read more…]

Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation to highlight updated results from phase 1/2 trial of DS-7300 in several types of cancer including lung, esophageal and prostate MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: … [Read more…]

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education webcast at 2:00 p.m. Eastern Time on Wednesday, September 28, 2022, focusing on Hybrid AF Therapy. The webcast will include … [Read more…]

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster … [Read more…]

Multicenter, open-label, dose-finding trial evaluating THIO sequenced with cemiplimab in patients with advanced non-small cell lung cancer CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical … [Read more…]

Data further reinforces the value of Foundation Medicine’s proprietary homologous recombination deficiency (HRD) signature CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present 14 abstracts at the 2022 European Society for Medical Oncology Congress being held virtually and in person in Paris … [Read more…]

LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #ConcertPharmaceuticals—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022. The on-demand webcast of the presentation may be accessed in the Investors section of the Company’s … [Read more…]

CAMBRIDGE, England, & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13th, 2022 at 10:00 a.m. ET. … [Read more…]

– Otenaproxesul demonstrated efficacy in acute pain clinical study conducted in the UK in 2019 TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the selection of a poster presentation of clinical data supporting otenaproxesul’s acute … [Read more…]